BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	asciminib Sensitive: B - Late Trials Novartis Press Release - 1 week (New B)	asciminib Sensitive: B - Late Trials Novartis Press Release - 1 week - (New B)
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	dasatinib Sensitive: A1 - Approval	dasatinib Sensitive: A1 - Approval
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	asciminib Sensitive: A1 - Approval	asciminib Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myeloid Leukemia CML	No biomarker No biomarker	Chronic Myeloid Leukemia CML	omacetaxine mepesuccinate Sensitive: A1 - Approval	omacetaxine mepesuccinate Sensitive: A1 - Approval
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	ponatinib Sensitive: A1 - Approval	ponatinib Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myeloid Leukemia CML	No biomarker No biomarker	Chronic Myeloid Leukemia CML	ponatinib Sensitive: A1 - Approval	ponatinib Sensitive: A1 - Approval
ABL1 T315I ABL1 T315I	Chronic Myeloid Leukemia CML	ABL1 T315I ABL1 T315I	Chronic Myeloid Leukemia CML	ponatinib Sensitive: A1 - Approval	ponatinib Sensitive: A1 - Approval
Chr t(1;16)(q12;q11.2) Chr t(1;16)(q12;q11.2)	Chronic Myeloid Leukemia CML	Chr t(1;16)(q12;q11.2) Chr t(1;16)(q12;q11.2)	Chronic Myeloid Leukemia CML	ponatinib Sensitive: A1 - Approval	ponatinib Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myeloid Leukemia CML	No biomarker No biomarker	Chronic Myeloid Leukemia CML	busulfan Sensitive: A1 - Approval	busulfan Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myelomonocytic Leukemia CMML	No biomarker No biomarker	Chronic Myelomonocytic Leukemia CMML	azacitidine Sensitive: A1 - Approval	azacitidine Sensitive: A1 - Approval
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	nilotinib Sensitive: A1 - Approval	nilotinib Sensitive: A1 - Approval
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	bosutinib Sensitive: A1 - Approval	bosutinib Sensitive: A1 - Approval
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	imatinib Sensitive: A1 - Approval	imatinib Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myelomonocytic Leukemia CMML	No biomarker No biomarker	Chronic Myelomonocytic Leukemia CMML	decitabine/cedazuridine Sensitive: A1 - Approval	decitabine / cedazuridine Sensitive: A1 - Approval
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	asciminib Sensitive: A1 - Approval	asciminib Sensitive: A1 - Approval
BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline	bosutinib Resistant: A2 - Guideline
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline	bosutinib Resistant: A2 - Guideline
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
No biomarker No biomarker	Chronic Myeloid Leukemia CML	No biomarker No biomarker	Chronic Myeloid Leukemia CML	bosutinib Sensitive: A2 - Guideline	bosutinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chronic Myeloid Leukemia CML	No biomarker No biomarker	Chronic Myeloid Leukemia CML	nilotinib Sensitive: A2 - Guideline	nilotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chronic Myeloid Leukemia CML	No biomarker No biomarker	Chronic Myeloid Leukemia CML	dasatinib Sensitive: A2 - Guideline	dasatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chronic Myeloid Leukemia CML	No biomarker No biomarker	Chronic Myeloid Leukemia CML	YD312 Sensitive: A2 - Guideline	YD312 Sensitive: A2 - Guideline
BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	Tyrosine kinase inhibitor Sensitive: A2 - Guideline	Tyrosine kinase inhibitor Sensitive: A2 - Guideline
BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 T315A BCR-ABL1 T315A	Chronic Myeloid Leukemia CML	BCR-ABL1 T315A BCR-ABL1 T315A	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 F317I BCR-ABL1 F317I	Chronic Myeloid Leukemia CML	BCR-ABL1 F317I BCR-ABL1 F317I	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 F317V BCR-ABL1 F317V	Chronic Myeloid Leukemia CML	BCR-ABL1 F317V BCR-ABL1 F317V	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 F317C BCR-ABL1 F317C	Chronic Myeloid Leukemia CML	BCR-ABL1 F317C BCR-ABL1 F317C	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline	dasatinib Resistant: A2 - Guideline
BCR-ABL1 Y253H BCR-ABL1 Y253H	Chronic Myeloid Leukemia CML	BCR-ABL1 Y253H BCR-ABL1 Y253H	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
BCR-ABL1 E255V BCR-ABL1 E255V	Chronic Myeloid Leukemia CML	BCR-ABL1 E255V BCR-ABL1 E255V	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
BCR-ABL1 F359I BCR-ABL1 F359I	Chronic Myeloid Leukemia CML	BCR-ABL1 F359I BCR-ABL1 F359I	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
BCR-ABL1 G250E BCR-ABL1 G250E	Chronic Myeloid Leukemia CML	BCR-ABL1 G250E BCR-ABL1 G250E	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline	bosutinib Resistant: A2 - Guideline
BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline	bosutinib Resistant: A2 - Guideline
BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	nilotinib Sensitive: A2 - Guideline	nilotinib Sensitive: A2 - Guideline
BCR-ABL1 L248V BCR-ABL1 L248V	Chronic Myeloid Leukemia CML	BCR-ABL1 L248V BCR-ABL1 L248V	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	olverembatinib Sensitive: B - Late Trials	olverembatinib Sensitive: B - Late Trials
BCR-ABL1 G250E BCR-ABL1 G250E	Chronic Myeloid Leukemia CML	BCR-ABL1 G250E BCR-ABL1 G250E	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 Q252H BCR-ABL1 Q252H	Chronic Myeloid Leukemia CML	BCR-ABL1 Q252H BCR-ABL1 Q252H	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 Y253H BCR-ABL1 Y253H	Chronic Myeloid Leukemia CML	BCR-ABL1 Y253H BCR-ABL1 Y253H	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E355G BCR-ABL1 E355G	Chronic Myeloid Leukemia CML	BCR-ABL1 E355G BCR-ABL1 E355G	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 L387M BCR-ABL1 L387M	Chronic Myeloid Leukemia CML	BCR-ABL1 L387M BCR-ABL1 L387M	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E459K BCR-ABL1 E459K	Chronic Myeloid Leukemia CML	BCR-ABL1 E459K BCR-ABL1 E459K	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 D276G BCR-ABL1 D276G	Chronic Myeloid Leukemia CML	BCR-ABL1 D276G BCR-ABL1 D276G	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E279K BCR-ABL1 E279K	Chronic Myeloid Leukemia CML	BCR-ABL1 E279K BCR-ABL1 E279K	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 H396R BCR-ABL1 H396R	Chronic Myeloid Leukemia CML	BCR-ABL1 H396R BCR-ABL1 H396R	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 F486S BCR-ABL1 F486S	Chronic Myeloid Leukemia CML	BCR-ABL1 F486S BCR-ABL1 F486S	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	ponatinib Sensitive: C1 - Off-label	ponatinib Sensitive: C1 - Off-label
TP53 mutation TP53 mutation	Chronic Myelomonocytic Leukemia CMML	TP53 mutation TP53 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C1 - Off-label	venetoclax Sensitive: C1 - Off-label
RUNX1 mutation RUNX1 mutation	Chronic Myelomonocytic Leukemia CMML	RUNX1 mutation RUNX1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
CSF3R T618I CSF3R T618I	Chronic Myeloid Leukemia CML	CSF3R T618I CSF3R T618I	Chronic Myeloid Leukemia CML	ruxolitinib Sensitive: C3 – Early Trials	ruxolitinib Sensitive: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Chronic Myeloid Leukemia CML	ASXL1 mutation ASXL1 mutation	Chronic Myeloid Leukemia CML	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Chronic Myelomonocytic Leukemia CMML	IDH2 mutation IDH2 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials	imatinib Resistant: C3 – Early Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	dasatinib + nilotinib Resistant: C3 – Early Trials	dasatinib + nilotinib Resistant: C3 – Early Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	PF-114 Sensitive: C3 – Early Trials	PF-114 Sensitive: C3 – Early Trials
CIP2A-H CIP2A-H	Chronic Myeloid Leukemia CML	CIP2A-H CIP2A-H	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
miR-146a expression miR-146a expression	Chronic Myeloid Leukemia CML	miR-146a expression miR-146a expression	Chronic Myeloid Leukemia CML	imatinib Sensitive: C3 – Early Trials	imatinib Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Chronic Myelomonocytic Leukemia CMML	IDH1 mutation IDH1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
NPM1 mutation NPM1 mutation	Chronic Myelomonocytic Leukemia CMML	NPM1 mutation NPM1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + nilotinib Sensitive: C3 – Early Trials	venetoclax + nilotinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + bosutinib Sensitive: C3 – Early Trials	venetoclax + bosutinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + ponatinib Sensitive: C3 – Early Trials	venetoclax + ponatinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + dasatinib Sensitive: C3 – Early Trials	venetoclax + dasatinib Sensitive: C3 – Early Trials
BCR-ABL1 Q252H BCR-ABL1 Q252H	Chronic Myeloid Leukemia CML	BCR-ABL1 Q252H BCR-ABL1 Q252H	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials	imatinib Resistant: C3 – Early Trials
BCR-ABL1 M351T BCR-ABL1 M351T	Chronic Myeloid Leukemia CML	BCR-ABL1 M351T BCR-ABL1 M351T	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials	imatinib Resistant: C3 – Early Trials
BCR-ABL1 L248V BCR-ABL1 L248V	Chronic Myeloid Leukemia CML	BCR-ABL1 L248V BCR-ABL1 L248V	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials	imatinib Resistant: C3 – Early Trials
BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials	imatinib Resistant: C3 – Early Trials
KRAS G12A KRAS G12A	Chronic Myeloid Leukemia CML	KRAS G12A KRAS G12A	Chronic Myeloid Leukemia CML	GT19077 Sensitive: C3 – Early Trials	GT19077 Sensitive: C3 – Early Trials
G0S2 overexpression G0S2 overexpression	Chronic Myeloid Leukemia CML	G0S2 overexpression G0S2 overexpression	Chronic Myeloid Leukemia CML	YD312 Sensitive: C3 – Early Trials	YD312 Sensitive: C3 – Early Trials
DNMT3A deletion DNMT3A deletion	Chronic Myeloid Leukemia CML	DNMT3A deletion DNMT3A deletion	Chronic Myeloid Leukemia CML	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
ASXL1 deletion ASXL1 deletion	Chronic Myeloid Leukemia CML	ASXL1 deletion ASXL1 deletion	Chronic Myeloid Leukemia CML	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
KDM4D mutation KDM4D mutation	Chronic Myeloid Leukemia CML	KDM4D mutation KDM4D mutation	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials	imatinib Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Chronic Myeloid Leukemia CML	DNMT3A mutation DNMT3A mutation	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials	YD312 Resistant: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Chronic Myeloid Leukemia CML	ASXL1 mutation ASXL1 mutation	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials	YD312 Resistant: C3 – Early Trials
ABL1 T315I ABL1 T315I	Chronic Myeloid Leukemia CML	ABL1 T315I ABL1 T315I	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 F317L ABL1 F317L	Chronic Myeloid Leukemia CML	ABL1 F317L ABL1 F317L	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 T315I + ABL1 M351T + ABL1 L387M ABL1 T315I + ABL1 M351T + ABL1 L387M	Chronic Myeloid Leukemia CML	ABL1 T315I + ABL1 M351T + ABL1 L387M ABL1 T315I + ABL1 M351T + ABL1 L387M	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 F359V ABL1 F359V	Chronic Myeloid Leukemia CML	ABL1 F359V ABL1 F359V	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 G250E ABL1 G250E	Chronic Myeloid Leukemia CML	ABL1 G250E ABL1 G250E	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 Y253H ABL1 Y253H	Chronic Myeloid Leukemia CML	ABL1 Y253H ABL1 Y253H	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 E255K ABL1 E255K	Chronic Myeloid Leukemia CML	ABL1 E255K ABL1 E255K	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 D276G ABL1 D276G	Chronic Myeloid Leukemia CML	ABL1 D276G ABL1 D276G	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 M351T ABL1 M351T	Chronic Myeloid Leukemia CML	ABL1 M351T ABL1 M351T	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
ABL1 L387M ABL1 L387M	Chronic Myeloid Leukemia CML	ABL1 L387M ABL1 L387M	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials	dasatinib Resistant: C3 – Early Trials
BCR-ABL1 A397P BCR-ABL1 A397P	Chronic Myeloid Leukemia CML	BCR-ABL1 A397P BCR-ABL1 A397P	Chronic Myeloid Leukemia CML	dasatinib Sensitive: C3 – Early Trials	dasatinib Sensitive: C3 – Early Trials

Chronic Myeloid Leukemia

Associations(261)

Associations
(261)